EGFR and breast cancer: Moreover, treatment of breast cancer cells and tumor-bearing mice with these EGFR targeted curcumin NPs led to decreased phosphoinositide 3-kinase signaling, a significant reduction in cancer cell viability, low drug clearance from the circulation, and significant suppression in tumor burden as compared with free curcumin and nontargeted NPs [68].